Objectives: Significant progress has been made in the treatment of locally advanced cervical cancer (CC); however, the management of recurrent and metastatic CC remains inadequate. Cisplatin (CDDP) is an effective radiosensitizer, but its single-agent activity in patients with advanced and recurrent CC, is disappointing, especially in patients previously treated with CDDP, with a best response rate of 13% (Long, J Clin Oncol 2005) . Oxaliplatin has preclinical activity in CDDP-resistant tumors, is active in colorectal cancer (a tumor not responsive to CDDP) and may have synergy with paclitaxel. Methods: Patients with recurrent or metastatic CC who had no prior chemotherapy except primary concurrent CDDP/radiation were treated with intravenous paclitaxel 175 mg/m 2 and intravenous oxaliplatin 130 mg/m 2 every 21 days. Response, as determined by RECIST criteria and confirmed every nine weeks, and toxicity were the primary outcomes. This is the completed data analysis of a standard Simon two-stage phase II study. Results: Of the 35 patients enrolled, 33 were treated. One patient died of cardiac arrest unrelated to treatment after one dose, leaving 32 evaluable patients. Median age was 56 (27-78); 30 had had prior radiation (23 with CDDP). Patients completed a mean of four cycles (range: 1-8). Two patients had a complete response and five had a partial response, for a total response rate of 7/32 (22%). There were also eight patients with stable disease (b30% decrease and 20% increase in consecutively documented target lesions) for an overall clinical benefit rate of 15/32 (47%). In patients who had clinical benefit, the mean time to best response was 10 weeks (range: 6-23) and the mean time to progression was 44 weeks (range: 9-181). A total of 126 cycles of paclitaxel and oxaliplatin were administered. There were 16 (12.7%) grade 3/4 hematologic toxic effects and 25 (19.8%) grade 3/4 nonhematologic toxic effects. One patient had a hypersensitivity reaction to paclitaxel. There were six dose reductions: three dose reductions were due to grade 3 neuropathy, one due to grade 3 thrombocytopenia, one due to a recurrent electrolyte imbalance, and one due to hematologic toxicity. There were no treatment-related deaths. Conclusions: The combination of paclitaxel and oxaliplatin is an effective regimen in patients with recurrent or persistent CC and is reasonably well tolerated. Comparison with CDDP or carboplatin-based regimens is warranted. Objectives: The purpose of this article was to report on the clinical outcomes of concurrent cisplatin and extended-field, intensity-modulated radiotherapy (EF-IMRT) for cervical carcinoma with extended follow-up. Methods: Forty-one patients with stage 1B2-IVA cervical cancer were treated with EF-IMRT and concurrent chemotherapy followed by high-dose-rate brachytherapy (HDRB) between 2001 and 2007 (Table 1) . Pelvic lymph node involvement was observed in 24 patients, and 10 of these patients had paraaortic nodal disease. Treatment volume included the cervix, uterus, parametria, presacral space, upper vagina, and pelvic, common iliac, and paraaortic nodes to the T12-L1 interspace. Patients were assessed for acute toxicity according to the NCI Common Toxicity Criteria for Adverse Events, Version 3.0 (Table 2 ). All late toxicity was scored with the Radiation Therapy Oncology Group late toxicity score (Table 3) . Results: All patients completed the prescribed course of EF-IMRT. All but one patient received HDRB. Median treatment time was 51 days. Acute grade ≥ 3 gastrointestinal toxicity, genitourinary toxicity, and myelotoxicity were observed in 1, 1, and 12 patients, respectively. Thirty-nine patients (95%) had a complete response to treatment. At the median follow-up of 37 months (range: 4-82), 15 patients (36%) developed a recurrence or progressive disease (local 3, regional 1, systemic 8, and systemic and locoregional 3) (Table 4) . Five-year actuarial locoregional control, recurrence-free survival, and overall survival rates were 77.9, 61, and 62%, respectively. The grade ≥ 3 toxicity rate for the entire cohort was 8%. Table 5 summarizes the relationship between recurrence pattern and FIGO stage. Conclusions: Our long-term follow-up in patients treated with EF-IMRT and concurrent chemotherapy demonstrated it to be well tolerated with acceptable acute and late toxicity. Locoregional control was good, with distant metastasis predominating as the most common mode of failure. Objectives: The purpose of this study was to investigate the potential effect of human papillomavirus (HPV) E6 small interfering RNA (siRNA) as a chemosensitizer and its synergistic effect on HPV-positive cervical squamous cell carcinoma treated with concurrent cisplatin (CDDP) chemotherapy. Methods: E6-specific siRNA was transfected into HeLa, SiHa, and CaSki cells, which were then treated with CDDP. Flow cytometry and senescence-associated β-galactosidase (SA-β-Gal) assay was performed to analyze the effect of siRNA. An in vivo xenograft model was established by subcutaneous injection of HeLa-luc cells into nude mice. Bioluminescence quantification and immunohistochemistry were used to confirm the in vivo effect of siRNA. Results: First, we confirmed that HPV18 E6 siRNAs achieved target-specific gene silencing without off-target effects and an interferon response. In an in vitro experiment, long-term combination therapy with HPV18 E6/E7 siRNA and CDDP synergistically suppressed cell growth and induced apoptosis and SA-β-Gal staining. In a xenograft model, concurrent CDDP chemotherapy and HPV18 E6/E7 siRNA treatment suppressed tumor growth through apoptosis, senescence, and antiangiogenesis. These in vitro and in vivo effects of combined therapy were significantly higher than those of either CDDP or HPV18 E6/E7 siRNA treatment. Conclusions: These results indicate that combined CDDP and synthetic HPV E6/E7 siRNA treatment synergistically augments their therapeutic effect on cervical squamous cell carcinoma and highlight the potential use of synthetic E6/E7 siRNA as a chemosensitizer in combination therapy. Objectives: Growing evidence supports the notion that heritable germline polymorphisms may modulate metastatic efficiency in cancer. MMP9 is a proteolytic enzyme implicated in tumor invasion, angiogenesis and growth; single-nucleotide polymorphisms (SNPs) and their catalytic component (rs17576) have been associated with nodal metastases in gastric cancer. SIPA1 is a activating protein involved in mitogen-induced cell cycle regulation, in which exonic (rs746429) and promoter (rs931127) SNPs have been associated with nodal metastases in breast cancer. The aim of this study was to determine whether these three functional SNPs are associated with nodal metastases in patients with stage Ib-IIa cervical cancer. Methods: Consecutive patients with stage Ib1-IIa cervical cancer who underwent complete pelvic lymph node dissection and contributed blood to a cervical cancer tissue bank were included in this case-control study. Cases were identified as patients with at least one positive lymph node (n = 101) and matched with controls with negative nodes (n = 273). Genotyping was performed on genomic DNA using an Applied Biosystems assay with validated primers to SNPs in MMP9 (rs17576) and SIPA1 (rs746429, rs931127). The distribution of each SNP was correlated with clinical variables. Data were analyzed using the χ 2/ and Fischer's exact test.
Results: No statistically significant difference was found in allelic distribution between cases and controls overall for any of the three SNPs, though the association between the GG genotype (rs931127) and nodal metastases approached significance in SIPA1 (OR = 1.23, P = 0.07). After controlling for stage, associations were present in each of the three SNPs. In stage IB2 patients (n = 53), all five patients with the MMP9 GG genotype (rs17576) had positive nodes compared with no controls and having at least one G allele increased a patient's risk of nodal metastases (OR = 3.2, P = 0.017). In stage IB1 patients (n = 304), in both SIPA1 SNPs, the G allele was associated with an increased risk of nodal metastases (rs76329 AG + GG: OR = 10.3, P =0.003; rs931127 AG + GG: OR = 2.3, P = 0.0012). After controlling for lymphvascular space invasion (LVSI), significant associations existed in both SIPA1 SNPs in patients with no LVSI (n =160). At rs76329, the G allele was associated with a higher risk of nodal metastases (GG: OR = 6.1, P = 0.042) and all patients with the AA genotype had negative nodal sampling. At rs931127, the GG genotype was also associated with an increased risk of nodal disease (OR = 4.5, P =0.016).
Conclusions: In this case-control study, the distribution of functional SNPs in MMP9 and SIPA1 differed statistically between cervical cancer patients with and those without nodal metastases after controlling for stage and LVSI. The LVSI association is particularly noteworthy as this may support alternative mechanisms of tumor spread. Although this is the largest such study to date, further work is warranted investigating the role of these and other SNPs in metastatic susceptibility in cervical cancer. Objectives: There is limited data addressing the epidemiology of multiple-type cervical HPV infections. Prophylactic vaccine trials report a low frequency of multiple-type infections. Our objectives were to (1) determine the frequency of multiple-type infection, and (2) determine if any types are identified in multiple infections more or less frequently than might be expected under the independence assumption. Methods: This is a retrospective analysis of women from one of 23 laboratories using type-specific HPV testing. Descriptive statistics were used to determine the rate of HPV infection by type. Two-type infection rates for each combination were calculated and the independence of the types was tested using χ 2 and Fisher's exact tests. A post hoc Bonferroni adjustment was used for multiple tests and P values less than 0.001 were considered statistically significant, with which a simultaneous significance level of 0.05 was ensured.
Results: HPV typing was performed on 73,563 women referred on the basis of their cytological screening results (Table 1) . HPV infection was present in 31.2% of patients. Multiple-type HPV infection was present in 25.1% of positive participants, with type 16 present in 30.0% of these. The remaining most frequent types involved, in decreasing order of frequency, were 53, 52, 31, 66, 6, 18, and 11 (Table 2) . Of the total participants with multiple infections, 82.6% had infections with two types. For the eight listed types (most notably HPV16), all were less likely to be found in multiple infections than would be expected by the frequency of each type alone under the assumption of independence. Next, we considered the frequency of multipletype infection based on phylogenetic virus species (Table 3) . The α9 species (types 16, 31, 33, 35, 52, 58, and 67) was most frequent, being involved in 57.8% of multiple infections. We also considered whether multiple-type infections were more likely to involve types within a phylogenetic species or between phylogenetic species. For all phylogenetic virus species except α9, both types in two-type multiple infections were less likely than expected to be from the same virus species. In contrast, in participants with two-type infections in which one type was from species α9, it was more likely than expected that the second type was also from α9 (P b 0.0001). Conclusions: Multiple-type HPV infections were present in 25.1% of HPV-positive women. There may be a competitive interaction between HPV types leading to less frequent involvement in multiple infections than would be expected if multiple infection was independent of HPV type. In particular, HPV type 16 is involved in fewer multiple infections than expected. HPV phylogenetic virus species α9, which includes type 16, appears to have an affinity for co-infection with another type from α9 in patients with multiple infections. 
